Nucrest Pharma Profile
Key Indicators
- Authorised Capital ₹ 1.00 Cr
- Paid Up Capital ₹ 1.00 Cr
- Company Age 5 Year, 2 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 3.51 Cr
- Satisfied Charges ₹ 3.60 M
- Revenue Growth -40.64%
- Profit Growth -23.81%
- Ebitda -55.44%
- Net Worth 56.88%
- Total Assets 0.76%
About Nucrest Pharma
Nucrest Pharma Private Limited (NPPL) is a Private Limited Indian Non-Government Company incorporated in India on 09 December 2019 (Five years and two months 17 days old ). Its registered office is in Mumbai, Maharashtra, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.00 Cr and a paid-up capital of Rs 1.00 Cr.
The company currently has active open charges totaling ₹3.51 Cr. The company has closed loans amounting to ₹3.60 M, as per Ministry of Corporate Affairs (MCA) records.
Vikram Panjwani and Ashok Panjwani serve as directors at the Company.
Company Details
- Location
Mumbai, Maharashtra, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
- Social Media -
Corporate Identity Details
- CIN/LLPIN
U24110MH2019PTC334133
- Company No.
334133
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
09 Dec 2019
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Who are the key members and board of directors at Nucrest Pharma?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Vikram Panjwani  | Director | 09-Dec-2019 | Current |
| Ashok Panjwani | Director | 09-Dec-2019 | Current |
Financial Performance of Nucrest Pharma.
Nucrest Pharma Private Limited, for the financial year ended 2023, experienced significant reduction in revenue, with a 40.64% decrease. The company also saw a substantial fall in profitability, with a 23.81% decrease in profit. The company's net worth Soared by an impressive increase of 56.88%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Nucrest Pharma?
In 2023, Nucrest Pharma had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
₹3.51 Cr
₹0.36 Cr
Charges Breakdown by Lending Institutions
- Others : 3.51 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 27 Mar 2024 | Others | ₹1.35 Cr | Open |
| 17 Aug 2023 | Others | ₹1.56 M | Open |
| 31 Dec 2020 | Others | ₹2.00 Cr | Open |
| 30 Mar 2024 | Others | ₹0.90 M | Satisfied |
| 28 Mar 2024 | Others | ₹2.70 M | Satisfied |
How Many Employees Work at Nucrest Pharma?
Unlock and access historical data on people associated with Nucrest Pharma, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Nucrest Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Nucrest Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.